株式会社極東書店トップ ＞ 商品一覧 ＞ Cannabinoids and Neuropsychiatric Disorders. 1st ed. 2021
商品詳細
Cannabinoids and Neuropsychiatric Disorders. 1st ed. 2021
・ISBN 978-3-030-57368-3 hard EUR 149.99
￥40,091.- (税込) ※（※）価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。
| 著者・編者 | Murillo-Rodriguez, Eric / Pandi-Perumal, S. R. / Monti, Jaime M. (eds.), |
|---|---|
| シリーズ | (Advances in Experimental Medicine and Biology) |
| 出版社 | (Springer Nature Switzerland AG, SZ) |
| 出版年月 | 2020 |
| ページ数 | 153 pp. |
| 言語 | ENG |
| ニュース番号 | ＜A04-60554＞ |
解説
This volume highlights the recent advances in the understanding of the endocannabinoid system and the likely benefit from the therapeutic effects of cannabinoid treatment in a variety of health issues.
Archeological evidence has shown that Cannabis has a long history of use for multiple purposes, including the treatment of medical conditions. The primary active constituent of the hemp plant Cannabis sativa, delta 9-tetrahydrocannabinol (?9-THC), causes euphoria, enhancement of sensory perception, tachycardia, antinociception, difficulties in concentration and impairment of memory, among other effects. Despite these undesirable effects, signaling is mostly inhibitory and suggests a putative role for cannabinoids as therapeutic agents by managing several diseases where inhibition of neurotransmitter release would be beneficial.
The themes of this book have been edited and written by world-leaders in the field, The contents of the volume aims at readers from a range of academic and professional disciplines, such as biomedicine, several areas of biology, neurology, clinical medicine and pharmacy.